‘Imminent’ Generic Approvals Expected To Help US FDA Meet On-Time Review Metric Retroactively
Executive Summary
ANDA action rate dipped below the 90% mandate in second fiscal quarter, another illustration of the effect the pandemic and other issues have on US FDA’s generic drug assessment system.
You may also be interested in...
COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.
Congress Already Preparing For User Fee Bills
Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.
FDA Avoided Half Of ANDA Pre-Approval Inspections During COVID By Using Alternative Tools
Records reviews are common now in lieu of an in-person inspection for US generic applications, but more virtual facility checks could be coming soon.